February 6, 2018

Quarterly Financial Summary
(For the first nine months of the fiscal year ending March 31, 2018)
[Under Japanese GAAP]
(Consolidated)

Listed Company: Zeria Pharmaceutical Co., Ltd. (Stock Exchange: First Section of Tokyo Stock Exchange)
Code Number: 4559 (URL: http://www.zeria.co.jp/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division TEL (03) 3661-1039
Scheduled date to submit the Quarterly Securities Report: February 9, 2018
Scheduled date to commence dividend payments: –
Preparation of supplementary documents to the quarterly financial results: None
Holding of quarterly financial results presentation: None

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2017 through December 31, 2017)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Nine months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
December 31, 2017	49,644	1.2	4,587	26.0	4,890	39.6	3,955	37.6
December 31, 2016	49,043	4.2	3,641	(4.0)	3,502	(7.0)	2,873	(13.8)

Note: Comprehensive income: For the nine months ended December 31, 2017: 4,708 million yen [–%]
For the nine months ended December 31, 2016: (3,090) million yen [–%]

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
December 31, 2017	76.35	–
December 31, 2016	54.10	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
December 31, 2017	112,614	61,758	54.7	1,213.10
March 31, 2017	114,357	63,504	55.4	1,192.73

Reference: Equity: As of December 31, 2017: 61,602 million yen March 31, 2017: 63,351 million yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2017	–	16.00	–	16.00	32.00
Year ending March 31, 2018	–	17.00	–		
Year ending March 31, 2018 (Forecast)				17.00	34.00

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2018 (April 1, 2017 through March 31, 2018)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	66,000	1.8	5,000	10.1	5,200	17.2	4,100	15.7	79.53

Note: Revision of the financial forecast most recently announced: Yes

* Notes

(1) Significant changes of subsidiaries during the nine months ended December 31, 2017 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: None
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: None
4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common stock)

1) Number of shares issued as of the end of the period (including treasury stock):
As of December 31, 2017: 53,119,190 shares As of March 31, 2017: 53,119,190 shares
2) Number of shares of treasury stock as of the end of the period:
As of December 31, 2017: 2,338,645 shares As of March 31, 2017: 4,192 shares
3) Average number of shares during the period (cumulative from the beginning of the fiscal year):
For the nine months ended December 31, 2017: 51,803,567 shares
For the nine months ended December 31, 2016: 53,115,221 shares

* Quarterly Financial Summary Is Not Required to Be Subjected to Quarterly Reviews.

* Cautionary Statement with respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.